Biological assessment of anti-TNF therapy in inflammatory bowel disease

Anti-tumor necrosis factor α (TNFα) therapy effectively induces and maintains remission in Crohn’s disease and ulcerative colitis. However, up to 40% of patients will not respond to anti-TNFα. Lack of response may stem from insufficient dose (low serum drug levels), the development of antibodies against the drug (immunogenicity), or the presence of predominantly fibrotic strictures. The goal of this study is to understand the mechanisms that underlie the lack of response to anti-TNFα in these patients.

Ingenuity pathway analysis.


- Roche Products Ltd.; PI: Azucena Salas

- Boehringer Ingelheim Pharmaceuticals, Inc.; PI: Azucena Salas

- Genentech Inc.; PI: Azucena Salas

- Leona and Harry Helmsley Trust; PI: Azucena Salas



Identification of inflammatory mediators in Crohn’s disease patients unresponsive to anti-TNF-a therapy.

Leal RF, Planell N, Kajekar R, Lozano JJ, Ordás I, Dotti I, Esteller M, Masamunt MC, Parmar H, Ricart E, Panés J, Salas A.


Gut 64(2): 233-42; 2014

doi: 10.1136/gutjnl-2013-306518. Epub 2014 Apr 3. / PMID: 24700437



Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.

Ordás I, Rimola J, Rodríguez S, Paredes JM, Martínez-Pérez MJ, Blanc E, Arévalo JA, Aduna M, Andreu M, Radosevic A, Ramírez-Morros AM, Pinó S, Gallego M, Jauregui-Amezaga A, Ricart E, Panés J.


Gastroenterology. 2014 Feb; 146(2): 374-82.e1

doi: 10.1053/j.gastro.2013.10.055. Epub 2013 Oct 29. / PMID: 24177375



Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study.

Ordás I, Rimola J, García-Bosch O, Rodríguez S, Gallego M, Etchevers MJ, Pellisé M, Feu F, González-Suárez B, Ayuso C, Ricart E, Panés J.


Gut. 2013 Nov; 62(11): 1566-72

doi: 10.1136/gutjnl-2012-303240. Epub 2012 Aug 30. / PMID: 22936673